Plus Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTV research report →
Range $25 – $25
Price Chart
About the company
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children.
- CEO
- Marc H. Hedrick
- IPO
- 2001
- Employees
- 28
- HQ
- Austin, TX, US
Get TickerSpark's AI analysis on PSTV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.36M
- P/E
- -0.14
- Fwd P/E
- 2.32
- PEG
- 0.00
- P/S
- 1.75
- P/B
- -5.17
- EV/EBITDA
- -0.37
- Div Yield
- 0.00%
- Gross Margin
- 59.67%
- Op Margin
- -832.57%
- Net Margin
- -859.47%
- ROE
- -591.74%
- ROIC
- -960.53%
Latest fiscal year · YoY change
- Revenue
- $5.21M-10.5%
- Gross Profit
- $4.77M-4.1%
- Op Income
- $-15,298,000
- Net Income
- $-22,386,000-72.5%
- EPS
- $-7.19+85.3%
- OCF Growth
- -96.8%
- FCF Growth
- -94.8%
- 52W High
- $23.43
- 52W Low
- $2.90
- 50D MA
- $4.30
- 200D MA
- $7.84
- Beta
- 1.40
- RSI (14)
- 44
- Avg Volume
- 159.31K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cerenome said Q3 showed early commercialization progress for CNSide while REYOBIQ hit key development milestones, but the company is still not providing full 2027 revenue guidance.· November 16, 2026
- CNSide moved from claims submission to revenue recognition, with $0.7 million of net diagnostic revenue and about $1.55 million of gross charges on 222 tests in Q3.
- Coverage expanded to about 190 million lives, or roughly 80% of U.S. private payer coverage, and commercial payers began paying claims in October.
- REYOBIQ met 3 of 4 2026 objectives: LM dose-optimization interim data were presented, GBM enrollment closed at 32 patients, and pediatric brain cancer enrollment began.
- Management said ReSPECT-LM is showing clean safety so far, predictable dosimetry, and an early disease-control signal, but formal efficacy endpoints are not yet ready.
- The company reiterated a 2026 exit target of about $10 million to $12.5 million in annualized gross billings for CNSide and said cash runway could extend into 2028 if the financing facility is fully accessed.
Total revenue for Q3 was $0.7 million, all from diagnostics, versus $1.4 million in the prior-year quarter, which was all grants. Gross charges on CNSide tests were about $1.55 million for 222 tests, and net diagnostic revenue was $0.7 million. Cost of revenue was about $0.9 million; R&D was $2.1 million, down year over year; SG&A was $5.2 million, up from $3.4 million. Operating loss was $7.5 million versus $4.5 million a year ago, and net loss was $8.7 million, or $1.14 per share, versus $4.4 million, or $1.03 per share last year. Cash, cash equivalents and investments were $4.9 million at September 30, down from $8.6 million at June 30; the company also raised just under $4 million in October and said it has access to a $20 million royalty and financing facility. For guidance, management reaffirmed 2026 exit gross billings of approximately $10 million to $12.5 million, said it expects collections to improve as billing history builds, and said testing, billing and collections could materially offset CNSide cash burn by the second half of 2027; if current trends continue, positive contribution could start late in 2027. For REYOBIQ, top-line data from both the LM multi-dose study and the GBM Phase II study are expected in mid-2027, and the company plans to start a randomized Phase IIb LM study in the second half of 2027.
Marc Hedrick framed the quarter as a milestone period across both diagnostics and therapeutics. He emphasized leadership additions, saying the company added a VP of Sales, a new Chief Business Officer, and promoted Eric Daniels to COO to support an increasingly integrated platform. His tone was constructive but measured: he highlighted achieved goals, but also said the company is not yet ready to provide detailed 2027 guidance until it has more operating data.
Andrew Sims focused on the step-by-step transition of CNSide from development to commercialization and repeatedly stressed gross billings rather than revenue as the better near-term metric. He broke out Q3 as 222 tests with about $1.55 million in gross charges, $0.7 million of net diagnostic revenue, and about $0.1 million in October cash collections, noting collections should accelerate as more claims process. He also cited the balance sheet and liquidity path, including $4.9 million of cash at quarter-end, just under $4 million raised in October, and access to a $20 million royalty and financing facility that could extend runway into 2028.
Analysts asked when the next LM update would come and whether it would include overall survival, neurological function and quality of life; management said top-line data should come in mid-2027 and should include progression-free survival, median overall survival, neurological function and quality of life. They also asked how well CNSide CSF tumor cell results correlate with MRI-based LM progression, and management said the measures often correlate but not perfectly, which is why CNSide’s higher sensitivity and specificity matter. On commercialization, management said it plans to start with 4 U.S. salespeople, expects them to be effective within about 90 days, and does not see lab capacity as a near-term constraint because the new facility should support growth for years.
The bull case from this call is that CNSide appears to be moving from launch to measurable commercial traction: more institutions and providers are ordering, repeat testing is happening, and payer coverage has expanded sharply. On the therapeutics side, REYOBIQ is showing clean early safety and predictable dosimetry in LM while management says it has FDA alignment on the next development steps.
The main risk is that the business is still early in monetization: only about $0.1 million of cash collections were received in October, management is still relying on gross billings as the main progress metric, and it said it needs 2 to 3 quarters of billing/collections before guiding to revenue. On the clinical side, the LM and GBM studies are not yet mature enough for formal efficacy conclusions, and management’s full 2027 forecast is still being withheld until more operating data are available.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 2.42M
- Float Shares
- 2.41M
of shares held by institutions
23 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.28M | ▲ 832.59K |
| Citadel Advisors LLC | 25.60K | ▲ 25.60K |
| Northern Trust Corp | 15.52K | ▼ 277.78K |
| Cubist Systematic Strategies, LLC | 11.66K | ▲ 1.44K |
| Tower Research Capital LLC (Trc) | 1.96K | ▲ 1.96K |
| Allied Private Wealth LLC | 496 | ▲ 496 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | ANDREWS RONALD ASBURY | other | 922 |
| Jul 1, 26 | Guse Kyle | other | 922 |
| Jul 1, 26 | ANDREWS RONALD ASBURY | other | 922 |
| Jul 1, 26 | Guse Kyle | other | 922 |
| Jul 1, 26 | van Es-Johansson An | other | 922 |
| Jul 1, 26 | van Es-Johansson An | other | 922 |
| Jul 1, 26 | HEDRICK MARC H | other | 6,387 |
| Jul 1, 26 | HEDRICK MARC H | other | 8,066 |
| Jul 1, 26 | HEDRICK MARC H | other | 1,986 |
| Jul 1, 26 | HEDRICK MARC H | other | 1,986 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PSTV coverage
Recent articles, reports, and earnings notes.
No research on PSTV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSTV report →Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
globenewswire.com · Sep 10
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
globenewswire.com · Aug 20
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
globenewswire.com · Aug 14
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
globenewswire.com · Aug 13
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Brokerages
defenseworld.net · Aug 3
Cerenome Launches as an Integrated CNS Oncology Company
globenewswire.com · Jul 31
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
globenewswire.com · Jul 28
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
globenewswire.com · Jul 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.